Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital tools

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

Roche - Basel

Roche delivers solid sales gain in 2012

New cancer products, such as Perjeta and Zelboraf, help growth

- PMLiVE

Merck KGaA starts third phase III trial for cancer hope TH-302

Unique method of action to target cells with low oxygen levels

- PMLiVE

Roche’s Avastin gains new US colon cancer approval

Patients can continue to use drug once disease progresses

- PMLiVE

India could hit Roche and BMS with compulsory licences

Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration

Daiichi Sankyo logo

Daiichi, ArQule cancer drug tivantinib flunks another trial

Fails to meet endpoint in colorectal cancer study

EISAI

Eisai’s farletuzumab fails ovarian cancer trial

Unable to improve progression-free survival

- PMLiVE

NHS failing to promote clinical trials to patients

NIHR mystery shoppers report says 91 per cent of sites have no information in reception area

- PMLiVE

Nexavar shows promise in thyroid cancer

Potential new indication for Bayer/Onyx drug

- PMLiVE

India’s Supreme Court wants tighter clinical trial regulation

Justice Lodha says illegal studies of investigational medicines causing “havoc to human life”

- PMLiVE

EMA to focus on efficiency, transparency and new legislation in 2013

Regulator also plans significant staff reorganisation

- PMLiVE

Fred Powell joins Celator as chief financial officer

Joins oncology specialist from OraPharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links